PLASMA CELL MYELOMA

This study tests whether adding elotuzumab to the standard maintenance drug lenalidomide can help keep multiple myeloma from returning after a stem cell transplant. About 113 people who had a transplant using their own stem cells will receive this combination therapy. The goal is…

This phase 3 study tests whether adding isatuximab to standard therapy (lenalidomide and dexamethasone) can delay progression to active multiple myeloma in people with high-risk smoldering myeloma. About 337 participants will receive either the three-drug combination or the two-d…

This phase 3 trial compares two drug combinations (VRd and CRd) as initial treatment for people newly diagnosed with multiple myeloma, a blood cancer. Over 1,000 participants receive one of the combos, followed by maintenance therapy to keep the cancer in check. The goal is to se…

This study tests whether the drug daratumumab, given after a stem cell transplant, can help keep multiple myeloma from coming back. About 31 participants will receive daratumumab as a follow-up treatment. The goal is to see if it improves how long people live without their cancer…

This study tests a new drug, iberdomide, combined with three standard treatments for people newly diagnosed with multiple myeloma. The goal is to find the best dose and see how well the combination kills cancer cells. About 49 adults will take part, and the study is currently act…

This study is for people with blood cancers like leukemia or lymphoma who have had a stem cell transplant or cell therapy. It tests a new COVID-19 vaccine (GEO-CM04S1) to see if it provides better protection against COVID-19 than the standard mRNA vaccines. The goal is to help th…

This early-phase study tests whether adding specially treated immune cells (called veto cells) from a donor can help stem cell transplants work better in people with blood cancers like leukemia or lymphoma. The goal is to help the donor cells grow without causing severe graft-ver…

This study looks at whether people with multiple myeloma who have had no signs of cancer for at least 3 years while on maintenance therapy can safely stop that therapy. Instead of continuing medication, they will be closely monitored to see if they remain cancer-free for at least…

This early-phase trial tests whether giving healthy donor NK cells along with two drugs (vactosertib and IL-2) is safe and helps the cells survive longer in people with advanced colorectal, stomach/esophageal, or blood cancers. About 12 participants will receive the combination t…

This study tests whether a combination of belantamab mafodotin (a targeted antibody-drug) and lenalidomide can eliminate leftover cancer cells in multiple myeloma patients who still have detectable disease after a stem cell transplant. The trial enrolls adults aged 18 and older w…

This study tests whether adding a drug called cyclophosphamide after a stem cell transplant can lower the risk of graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. The trial includes 35 adults with various blood cancers or sever…

This study follows 350 stem cell transplant survivors to see how their heart, lungs, and muscles work together over two years. Researchers measure exercise capacity and other health markers to learn why transplant survivors have a higher risk of heart disease. Participants includ…

This study looks at whether a special website can help women with cancer make better decisions about preserving their ability to have children after treatment. About 130 women with certain cancers (like breast or lymphoma) will use the website or get usual care. The goal is to se…